Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation boost may help immunotherapy fight lung cancer

NCT ID NCT03176173

Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding high-dose, precisely targeted radiation to standard immunotherapy can improve outcomes for people with stage IV non-small cell lung cancer. Forty-five adults who were already on immunotherapy received radiation to some of their tumors. Researchers measured how long the cancer stayed under control and whether tumors shrank.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
image-guided radiation therapy (IGRT) plus immunotherapy (anti-PD-1 or anti-PD-L1)
What this could lead to
If it works, this combination could help control metastatic lung cancer better than immunotherapy alone.
What could go wrong
This is a small, completed phase II trial with only 45 participants. Results may not apply to all patients, and radiation can cause side effects like fatigue or lung inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

45 people

The number who actually took part.

Started

Jun 2017

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Has stage IV non-small cell lung cancer, or initially stage I-III disease with distant metastatic recurrence 2. Age ≥ 18 3. Has been receiving anti-PD-1 or anti-PD-L1 immunotherapy for at least four weeks (refer to section 4.2.1) 4. Has had restaging imaging after initiation of immunotherapy, at least 4 weeks after pre-immunotherapy baseline imaging. CT or PET/CT of at least chest/upper abdomen must be performed within 4 weeks prior to registration. For patients with history of brain metastases, brain MRI or CT is required within 4 weeks of registration; for other patients brain MRI or CT is required within 12 weeks of registration. Diagnostic PET/CT performed as part of radiation simulation can be used as the restaging imaging. 5. Most recent imaging shows measurable disease as defined by RECIST 1.1 6. Evaluation by a Stanford medical oncologist must show: 1. The patient is expected to continue on immunotherapy for at least three more months 2. Imaging must show response, stable disease, or modest progression 3. If there is modest progression, the patient must be clinically stable in terms of performance status and overall disease-related symptoms 7. Has at least one extracranial tumor safely treatable with radical-dose radiation therapy and that has not been previously treated with radiation 8. ECOG performance status 0-2 9. Has the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Untreated brain metastases, if not planned to be treated in this course of radiation therapy * Pregnancy or women of childbearing potential not willing/able to use contraception during protocol treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stage IV non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stage IV non-small cell lung cancer

Contacts and locations

Locations

  • Stanford University, School of Medicine

    Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.